CASP1 and atherosclerosis: VX-765, a selective caspase 1 inhibitor, reduces activation and activity of caspase 1 and antagonizes NLRP3 inflammasome assembly and activation in the context of several inflammatory disorders and diseases such as atherosclerosis, sepsis, or alzheimer disease (Jin et al., 2022; Wu et al., 2021; Flores et al., 2020).